Clinical Trials Logo

Driving Impaired clinical trials

View clinical trials related to Driving Impaired.

Filter by:

NCT ID: NCT06111989 Recruiting - Stroke Clinical Trials

Fitness to Drive Among Stroke Patients

Start date: March 1, 2022
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to learn more about who can continue driving a car after a stroke. The focus of this study is on the relationship between cognitive abilities and fitness-to-drive. Participants will be asked to perform an extended neuropsychological testing and a real life on-road test, conducted by a professional driving instructor. Feedback will be given to the participants on request.

NCT ID: NCT06059677 Recruiting - Driving Impaired Clinical Trials

Cannabis Consumption and Driving Impairment Assessment on a Closed Course

Start date: October 3, 2023
Phase: Phase 2
Study type: Interventional

In a true experiment, roughly 300 volunteer participants will smoke active cannabis, a corresponding placebo, or no substance at all (control). Next, participants will complete a drive test and then be observed by actual California Highway Patrol (CHP) officers who will attempt to classify participants as impaired or unimpaired. CHP Officers will evaluate participants in the context of driving (i.e., while following participants in an actual patrol car), as part of a roadside behavioral assessment (i.e., the Advanced Roadside Impaired Driving Enforcement, or ARIDE, battery, which includes Standardized Field Sobriety Tests, or SFSTs), and as part of a Drug Recognition Expert (DRE) evaluation conducted indoors.

NCT ID: NCT05703360 Not yet recruiting - Stroke Clinical Trials

Effectiveness of AV-stimulation in Immersive VR to Improve Visual Perception and Driving Performance

Re:DriVR
Start date: December 1, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate the effectiveness of an immersive virtual-reality (IVR) based stimulation program, in improving visual perception for people who have lost their driver's license due to perceptual or cognitive impairments. The main questions it aims to answer are: 1. Can the 6-week IVR stimulation program help improve driving performance? 2. Will participants experience improvement in visual detection and perception after training? Study Design Summary: - Participants will be randomized into a waitlist group or intervention-first group - The VR-based intervention will consist of training every 2 days for six weeks - Waitlist group will wait 6 weeks before starting intervention at study midpoint (week 7) - Intervention-first group will begin with intervention (week 1-6) and then stop intervention at study midpoint - Participants will complete tests related to driving performance, visual attention, and visual fields at the start of study, midpoint, and end of study Researchers will analyze data for changes from baseline in outcome measures.

NCT ID: NCT05537116 Enrolling by invitation - Driving Impaired Clinical Trials

Evaluation of an Interactive Mobile Phone-Based Brief Intervention to Reduce Substance-Impaired Driving

Start date: October 18, 2022
Phase: N/A
Study type: Interventional

Substance-Impaired Driving among emerging adults remains a significant public health concern and may be the single riskiest substance-related outcome among young adults. Brief Interventions (BIs) have been shown to reduce alcohol-impaired driving among this age group, but are not often implemented - despite their demonstrated efficacy - because it is not economically feasible to deliver in-person BIs to all emerging adult substance users. The present study will be the first to examine whether a text-messaging-based cannabis-impaired driving BI significantly decreases cannabis-impaired driving among emerging adult cannabis users compared to an informational control. Participants will be 240 emerging adults who endorse driving after cannabis use (or combined alcohol and cannabis use) at least three times in the past 3 months. After completing baseline measures, participants will be randomly assigned to receive either: a) substance use information, b) a substance-impaired driving personalized feedback intervention, or c) a substance-impaired driving personalized feedback intervention plus interactive text messages. Participants will complete outcome measures 3 and 6 months post-intervention. Repeated measures mixed modeling analyses will be used to determine whether the intervention significantly reduces substance-impaired driving over time. The project has two specific aims: 1) to evaluate a text based cannabis-impaired driving intervention in a randomized clinical trial, and 2) to determine whether the use of interactive text-messages sustains intervention effects over time.

NCT ID: NCT05273658 Withdrawn - Clinical trials for Alcohol Intoxication

Effects of Cannabis/Alcohol on Driving Performance and Field Sobriety Tests

Start date: August 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The overarching aim of this study is to examine the impact of acute cannabis and alcohol administration on driving performance, as well as identify methods for detecting driving under the influence of these substances. One-hundred twenty-five healthy volunteers will be randomized into one of 5 conditions; those who receive 1) low dose alcohol and placebo cannabis, 2) low dose alcohol and tetrahydrocannabinol (THC), 3) high dose alcohol and placebo cannabis, 4) placebo alcohol and THC, and 5) double placebo. Cannabis inhaled ad libitum and/or ingested alcohol will take place at the beginning of the day followed by the completion of driving simulations, components of the Drug Recognition Expert (DRE) evaluations, and bodily fluid draws (e.g., blood, oral fluid/saliva, breath) over the subsequent 4 hours after ingestion. The purpose of this study is to determine (1) the impact of Δ9-THC on driving performance with and without concurrent alcohol ingestion (2) the duration of driving impairment in terms of hours from initial use, (3) the relationship between performance on the DRE measures and cannabis/alcohol ingestion, and 4) if saliva or expired air can serve as a useful adjunct to the field for blood sampling.

NCT ID: NCT04948385 Completed - Driving Impaired Clinical Trials

Driving Performance After Deep Sedation for Outpatient Endoscopy

Start date: February 6, 2019
Phase: Phase 4
Study type: Interventional

Many drugs used during anesthesia can reduce alertness and therefore present potential risks when driving a vehicle (risk of accident). Some scientific societies recommend not driving for 12 to 24 hours after sedation or general anesthesia. However, there are conflicting data in the literature showing that general anesthesia in healthy volunteers does not impair driving ability as early as 2 hours after the end of anesthesia. This need not to drive requires the outpatient to have an escort. Unfortunately, some patients find it difficult to benefit from an adult escort, which can lead to last minute cancellations, absences or the need for a classic overnight hospital stay. The main objective of the study is to compare with a simulator the driving performances of patients who have benefited from deep sedation for an outpatient endoscopic digestive procedure when they have met the discharge criteria to the performances of their escorts in order to determine if the conditions are as safe to let them drive home.

NCT ID: NCT04648735 Completed - Clinical trials for Mild Cognitive Impairment

Driving Evaluation and Fitness for Persons With Cognitive Impairments

Start date: August 1, 2015
Phase: N/A
Study type: Interventional

Driving is an important activity for older adults because it frequently relates to personal independence and wellbeing. This study compared the driving behaviors of older drivers with normal cognition and with MCI in unfamiliar driving situations and difficult maneuvers, and explored the practice effect on driving performance of drivers with MCI. This study used an observational, cross-section research design.

NCT ID: NCT04587609 Completed - Driving Impaired Clinical Trials

Reducing Cell Phone Use While Driving Among High Risk UBI Auto Policy Holders

Start date: March 1, 2021
Phase: N/A
Study type: Interventional

Insurance User Based Insurance (UBI) users will be invited to participate in a randomized control trial where they will be randomized into 1 of 4 arms: (Arm 1) standard UBI, (Arm 2) Standard UBI + Free phone mounts (Arm 3) Commitment + Habit Tips, (Arm 4) Gamification + Social Competition,(Arm 5) Contest Financial Incentives. Each successive arm will experience all of the elements that the lower-numbered arms will.

NCT ID: NCT04330196 Completed - Clinical trials for Roux-en-Y Gastric Bypass

Effect of Postprandial Hyperinsulinaemic Hypoglycaemia on Driving Performance.

DEEP1C
Start date: July 8, 2020
Phase: N/A
Study type: Interventional

The primary objective of this study is to assess the effect of the natural course of postprandial hypoglycemia vs. a postprandial euglycaemic condition on driving performance in individuals with confirmed postprandial hyperinsulinaemic hypoglycaemia after gastric-bypass surgery.

NCT ID: NCT03656029 Completed - Clinical trials for Cognitive Impairment

Dose-response of Cannabis and Driving

Start date: June 4, 2021
Phase: Phase 2
Study type: Interventional

Epidemiological studies have established a link between collisions while driving and cannabis use. With the changing legal landscape around cannabis, there is much interest in determining per se limits of cannabis while driving. The present study will evaluate driving on a driving simulator after smoking placebo or cannabis with 3 different levels of THC. THC is the active component in cannabis and blood, urine and oral fluid levels of THC will be correlated with driving impairment.